APB-O-001

APB-O-001 is an RNA interference (RNAi) therapeutic candidate being developed by Aprilbio in collaboration with Curigin for the treatment of mixed hyperlipidemia. Currently in the discovery stage, the program utilizes RNAi technology to target and silence specific genes involved in lipid metabolism. The asset is part of a strategic partnership that combines Curigin's expertise in RNAi and gene silencing with Aprilbio's drug development capabilities, potentially leveraging Aprilbio's proprietary SAFA (Serum Albumin Fragment Associated) technology to enhance the pharmacokinetic profile and half-life of the oligonucleotide. While the specific molecular target remains undisclosed, the drug is designed to address the dysregulation of cholesterol and triglycerides associated with mixed hyperlipidemia.